ArticleBMC rheumatology2026
Serum ICAM-1 and VCAM-1 as markers of endothelial activation in ankylosing spondylitis and psoriatic arthritis: a cross-sectional study.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) have increased cardiovascular risk beyond traditional factors. Endothelial activation is an early and potentially reversible stage of atherogenesis, and circulating adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) have been proposed as markers of vascular involvement in inflammatory diseases. This study aimed to compare serum ICAM-1 and VCAM-1 levels in patients with ankylosing spondylitis and psoriatic arthritis versus controls, and to examine their associations with disease activity, systemic inflammatory burden, cardiovascular risk profile, and treatment status.
methodsThis cross-sectional study included 154 participants recruited between 2023 and 2024, including 83 patients with AS, 40 with PsA, and 31 controls. Disease activity was assessed using ASDAS-CRP (AS) and DAS28-CRP (PsA). Inflammatory markers, lipid profile, cardiovascular risk scores, and treatment history were recorded. Serum ICAM-1 and VCAM-1 concentrations were measured by enzyme-linked immunosorbent assay. Group comparisons used Kruskal-Wallis and Mann-Whitney U tests; correlations used Spearman or Pearson coefficients as appropriate. Multivariable linear regression was applied to identify independent predictors of VCAM-1.
resultsSerum VCAM-1 and ICAM-1 levels did not differ significantly between AS, PsA, and controls. VCAM-1 showed positive correlations with C-reactive protein (ρ = 0.247, p = 0.002) and erythrocyte sedimentation rate (ρ = 0.163, p = 0.044), whereas ICAM-1 showed no significant associations with inflammatory, metabolic, or vascular parameters. In multivariable analysis, body mass index was the only independent predictor of VCAM-1 (β = 0.198, p = 0.027). In AS, higher disease activity defined by ASDAS-CRP > 2.1 was associated with higher CRP (p = 0.002), ESR (p = 0.04), and VCAM-1 concentrations (p = 0.002). Biologic-naïve patients had higher VCAM-1 levels than treated patients (p = 0.046), while those receiving Janus kinase inhibitors had lower VCAM-1 compared with biologic-naïve individuals (p = 0.014).
conclusionsAlthough ICAM-1 and VCAM-1 levels were comparable between patients and controls, VCAM-1 reflected inflammatory activity and treatment status, particularly in AS. VCAM-1 may represent a more sensitive marker of endothelial activation than ICAM-1 in treated spondyloarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.